Hadasit Bio Holdings Portfolio Company Tolarex Ltd. to Commence Phase I/IIa Trial of a Treatment for GVHD

Published: Apr 20, 2009

EIN KEREM, Israel--(BUSINESS WIRE)--Tolarex, a Hadasit Bio Holdings Ltd (HBL) portfolio company, announced today that it has received approval by the Ministry of Health of Israel to begin a phase I/IIa clinical trial of its treatment for graft-versus-host disease (GVHD).

Back to news